Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothAPI & Intermediates Manufacturers with exports to >30 countries

            Contact the Supplier

            Lead Product(s): Bacterial Lysates

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Broncho-Vaxom

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 06, 2020

            Details:

            AstraZeneca granted an exclusive right to import and distribute the immunological therapy Broncho-Vaxom® for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nintedanib Esylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Nintib

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nintedanib Esylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            In a recently published INBUILDtm trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Formoterol Fumarate,Glycopyrronium Bromide,Fluticasone Propionate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2020

            Details:

            AIRZ-FF is India's first Glycopyrronium + Formoterol + Fluticasone combination, exclusively studied in the Indian population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Olopatadine Hydrochloride,Mometasone Furoate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 27, 2020

            Details:

            Hikma will commercialize Ryaltris™ in the US following approval with the ability to produce the product utilizing its nasal manufacturing capabilities in Columbus, Ohio.